Equities

Hangzhou Biotest Biotech Co Ltd

688767:SHH

Hangzhou Biotest Biotech Co Ltd

Actions
Health CareMedical Equipment and Services
  • Price (CNY)24.51
  • Today's Change-5.58 / -18.54%
  • Shares traded211.81k
  • 1 Year change-20.73%
  • Beta--
Data delayed at least 15 minutes, as of Sep 13 2024 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,9172,0401,728
Total Receivables, Net6740156
Total Inventory99135142
Prepaid expenses2.84206.60
Other current assets, total0.190.190.12
Total current assets2,0872,2352,033
Property, plant & equipment, net262245332
Goodwill, net------
Intangibles, net20921420
Long term investments7.774443
Note receivable - long term------
Other long term assets------
Total assets2,5802,7522,432
LIABILITIES
Accounts payable5889224
Accrued expenses212626
Notes payable/short-term debt0.590.355.64
Current portion long-term debt/capital leases2.455.102.28
Other current liabilities, total685059
Total current liabilities149171318
Total long term debt02.194.55
Total debt3.047.6412
Deferred income tax0.711.16--
Minority interest5.511.041.05
Other liabilities, total8.69151.25
Total liabilities164190324
SHAREHOLDERS EQUITY
Common stock107107107
Additional paid-in capital813815815
Retained earnings (accumulated deficit)1,5101,6381,185
Treasury stock - common(15)----
Unrealized gain (loss)------
Other equity, total(0.36)1.210.70
Total equity2,4152,5612,107
Total liabilities & shareholders' equity2,5802,7522,432
Total common shares outstanding106107107
Treasury shares - common primary issue0.4500
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.